Calidi Biotherapeutics, Inc 8-K, filed Jun 18, 2026
Calidi Biotherapeutics, Inc. (CLDI)
About this 8-K
Calidi Biotherapeutics, Inc filed this 8-K on June 18, 2026, reporting on events of June 12, 2026.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 12, 2026, Calidi Biotherapeutics, Inc., (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the record date of April 17, 2026, there were 15,228,625 shares of Common Stock issued and outstanding and entitled to vote.
At the Annual Meeting, 8,420,006 shares of Common Stock, representing approximately 55.29% of the total number of shares of Common Stock entitled to vote, were represented in person or by proxy, constituting a quorum. Set forth below are the voting results from the proposals presented for a stockholder vote at the Annual Meeting, each of which received a sufficient number of votes to pass.
| 1. | Election of Class III Director Nominee. The stockholders elected Scott Leftwich as Class III Director of the Company by a plurality of the votes cast, and without contest, to serve a three-year term until the 2029 Annual Meeting of Stockholders or until his successor has been duly elected. |
| NAME | FOR | WITHHLED | BROKER NON-VOTE | |||
| Scott Leftwich | 3,267,620 | 1,376,756 | 3,584,915 |
| 2. | Ratification of the appointment of Auditor. Stockholders approved and ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm to audit the consolidated financial statements of the Company for the fiscal year ending December 31, 2026. |
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE | |||
| 6,672,912 | 304,009 | 1,443,085 | - |
| 3. | Reverse Stock Split. Stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to, at the discretion of the Board of Directors, effect a reverse stock split with respect to the Company’s shares of issued and outstanding Common Stock, which consists of Voting Common Stock and Non-Voting Common Stock, at a ratio between 1-for-2 and 1-for-16 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement. |
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE | |||
| 6,512,621 | 1,835,715 | 71,670 | - |
| 4. | 2023 Plan Amendment. Stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan (the “2023 Plan”), to increase the aggregate number of shares of common stock authorized for grant under the 2023 Plan from 282,815 to 1,950,000. |
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE | |||
| 2,029,740 | 1,423,374 | 1,381,977 | 3,584,915 |
All the proposals presented for a vote at the Annual Meeting were approved by the Company’s stockholders. The results reported above are final voting results. No other matters were considered or voted upon at the Annual Meeting, except a proposal to adjourn the meeting to a later date, if necessary, to permit further solicitation and vote proxies in the event there were not sufficient votes in favor of the proposals. Based upon the voting results, the latter was not applicable.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Calidi Biotherapeutics, Inc. | ||
| Dated: June 18, 2026 | ||
| By: | /s/ Andrew Jackson | |
| Name: | Andrew Jackson | |
| Title: | Chief Financial Officer | |